Ahead of the Healthcare Expo Taiwan, the MEDTEX Summit Asia, an Asian medical technology innovation forum scheduled for December 3–4, will feature 15 international startups incubated by major pharmaceutical companies coming to Taiwan to seek funding. Competing on the local front will be Taiwanese companies such as Alar Pharmaceuticals and Pharmosa Biopharm, showcasing their technologies. This event is anticipated to spark an investment boom in the biotech industry.
This year’s forum focuses on technological innovation and capital collaboration, attracting domestic venture capitalists, private equity funds, corporate leaders, and professional investors eager to identify potential investment targets. According to the Institute for Biotechnology and Medicine Industry (IBMI), in addition to attracting international procurement teams through the Healthcare Expo, the forum aims to bring international startups to Taiwan to seek funding, expanding the horizons of Taiwan’s investment community and demonstrating the nation’s capital strength to the world.
Under the theme "Leading Innovation, Investing in the Future", the forum will feature 20 international speakers and invite tech giants and top venture capital firms to share their strategies for technology and investment in 2025. It will also gather 15 startups incubated by major pharmaceutical companies such as Johnson & Johnson and Merck, along with international venture capital firms like Insight Partners, Temasek, MassMutual, and ARCH Venture Partners. For many, this marks their first visit to Taiwan in search of strategic capital partnerships, making this pre-Healthcare Expo event highly anticipated.
One notable participant is Arbor Biotechnologies, founded by CRISPR pioneer Dr. Feng Zhang. Backed by investors including ARCH Venture Partners and Temasek, Arbor Biotechnologies has a fundraising scale approaching NT$10 billion. The company’s core technology, a next-generation CRISPR gene-editing platform, can precisely edit over 93% of the human genome. Arbor focuses on developing gene therapies for genetic and neurodegenerative diseases. Represented by CTO David Cheng, the company will seek Series C funding during its Taiwan visit.
Another standout is Tempo Therapeutics, whose primary investors include J&J and Galaxy Partners. The company specializes in innovative microporous hydrogel biomaterials that promote tissue regeneration while reducing immune responses. Its main clinical applications include wound regeneration for skin cancer, gastrointestinal/abdominal, and head and neck tumors. CEO Westbrook Weaver will lead its Series A funding efforts, with the company’s current valuation at US$21 million.
Also participating is ImmuneBridge, supported by investors like M Ventures (Merck’s venture capital arm) and Insight Partners, which manages over US$90 billion in assets. ImmuneBridge’s unique immune stem cell expansion technology can amplify hematopoietic stem cells by 100,000-fold, with applications in cancer, autoimmune diseases, and HIV treatment. Chief Scientist Nina Horowitz will represent the company in seeking seed-extension funding at the forum.
With the convergence of international startups and Taiwan’s investment ecosystem, the MEDTEX Summit Asia aims to foster innovation and capital cooperation, paving the way for a thriving biotech investment landscape and setting the stage for the Healthcare Expo Taiwan.
Resource: 醫療科技展前暖身 國際新創、台企募資大PK
